Microrna-9-5p-CDX2 axis: A useful prognostic biomarker for patients with stage II/III colorectal cancer

• Nishiuchi, Aya

  Department of Surgery, Graduate School of Medicine, Kyoto University

• Hisamori, Shigeo

  Department of Surgery, Graduate School of Medicine, Kyoto University

• Sakaguchi, Masazumi

  Department of Surgery, Graduate School of Medicine, Kyoto University･Department of Gastroenterological Surgery, Osaka Red Cross Hospital

• Fukuyama, Keita

  Department of Clinical Oncology, Kyoto University Hospital

• Hoshino, Nobuaki

  Department of Surgery, Graduate School of Medicine, Kyoto University

• Itatani, Yoshiro

  Department of Surgery, Graduate School of Medicine, Kyoto University

• Honma, Shusaku

  Department of Surgery, Graduate School of Medicine, Kyoto University

• Maekawa, Hisatsugu

  Department of Surgery, Graduate School of Medicine, Kyoto University

• Nishigori, Tatsuto

  Department of Surgery, Graduate School of Medicine, Kyoto University

• Tsunoda, Shigeru

  Department of Surgery, Graduate School of Medicine, Kyoto University

• Obama, Kazutaka

  Department of Surgery, Graduate School of Medicine, Kyoto University

• Miyoshi, Hiroyuki

  Division of Experimental Therapeutics, Department of Gastrointestinal Surgery, Graduate School of Medicine, Kyoto University

• Shimono, Yohei

  Department of Biochemistry, School of Medicine, Fujita Health University

• Mark Taketo, M.

  Division of Experimental Therapeutics, Graduate School of Medicine, Kyoto University

• Sakai, Yoshiharu

  Department of Surgery, Graduate School of Medicine, Kyoto University

Abstract

A lack of caudal-type homeobox transcription factor 2 (CDX2) protein expression has been proposed as a prognostic biomarker for colorectal cancer (CRC). However, the relationship between CDX2 levels and the survival of patients with stage II/III CRC along with the relationship between microRNAs (miRs) and CDX2 expression are unclear. Tissue samples were collected from patients with stage II/III CRC surgically treated at Kyoto University Hospital. CDX2 expression was semi-quantitatively evaluated by immunohistochemistry (IHC). The prognostic impacts of CDX2 expression on overall survival (OS) and relapse-free survival (RFS) were evaluated by multivariable statistical analysis. The expression of miRs regulating CDX2 expression and their prognostic impacts were analyzed using The Cancer Genome Atlas Program for CRC (TCGA-CRC). Eleven of 174 CRC tissues lacked CDX2 expression. The five-year OS and RFS rates of patients with CDX2-negative CRC were significantly lower than those of CDX2-positive patients. Multivariate analysis of clinicopathological features revealed that CDX2-negative status is an independent marker of poor prognosis in stage II/III CRC. miR-9-5p was shown to regulate CDX2 expression. TCGA-CRC analysis showed that high miR-9-5p expression was significantly associated with poor patient prognosis in stage II/III CRC. In conclusion, CDX2, the post-transcriptional target of microRNA-9-5p, is a useful prognostic biomarker in patients with stage II/III CRC.

Journal

• Cancers

  Cancers 11 (12), 2019-12-01

  MDPI AG

Keywords

• CDX2
• stage II/III colorectal cancer
• microRNA-9-5p

Details

• CRID: 1050848249723625856
• NII Article ID: 120006846477
• ISSN: 20726694
• HANDLE: 2433/250985
• Text Lang: en
• Article Type: journal article
• Data Source:
  • IRDB
  • CiNii Articles